May 8, 2008 - US WorldMeds, a Kentucky-based specialty pharmaceutical company, today announced that it has completed development of and filed a provisional patent for Dantrolene Sodium for Injection that will dramatically enhance the medication's reconstitution time to 20 seconds or less. Introduction of this fast reconstituted Dantrolene Sodium for Injection is expected to represent an advancement in the pharmacotherapy of patients experiencing malignant hyperthermia during surgery.
Dantrolene Sodium for Injection is already sold as a generic product by US WorldMeds, which has captured approximately 60% of the US market since the product's launch on October 4, 2007. It is the only generic substitute for Dantrium(R) Intravenous. US WorldMeds' improved reconstitution product is expected to meet all current FDA approved release specifications. US WorldMeds plans to file a submission in 2008 to obtain FDA approval of its Dantrolene Sodium for Injection with improved reconstitution.
The details can be read here.
No comments:
Post a Comment